Bank of America Securities released a research report, and it was reported that$Wuxi Biologics (02269.HK) $Subsidiaries may be removed from the unverified list of the US Department of Commerce, believing that they are moving in the right direction, as US reviews of potential positive feedback may lead to the eventual delisting of its Wuxi subsidiary, which means that the official decision has yet to be implemented. In addition, Wuxi Biologics added 47 integrated projects in the first four months of this year, compared with 138 for the whole of 2021, reflecting that the company's business and customers were not affected by the unverified list in the United States.

Taking into account the positive trend of delisting, increased customer confidence and reduced risk of future volatility, BofA raised its target price for Wuxi Biologics from HK $78 to HK $91.80, but reiterated its "neutral" rating due to the uncertainty of the de-listing decision.